Pharmaceutical companies views on a health technology assessment (HTA) entity in Saudi Arabia

被引:12
作者
Al-Omar, Hussain Abdulrahman [1 ,2 ]
Attuwaijri, Abdulaziz Abdulhadi [3 ]
Aljuffali, Ibrahim Abdulrahman [4 ,5 ,6 ]
机构
[1] King Saud Univ, Coll Pharm, Dept Clin Pharm, POB 2457, Riyadh 11451, Saudi Arabia
[2] Minist Hlth, Saudi Hlth Technol Assessment Ctr, Riyadh, Saudi Arabia
[3] Minist Hlth, Riyadh, Saudi Arabia
[4] King Saud Univ, Coll Pharm, Dept Pharmaceut, POB 2457, Riyadh 11451, Saudi Arabia
[5] Minist Hlth, Minister Hlth Pharmaceut Sect Dev, Riyadh, Saudi Arabia
[6] Minist Hlth, Program Hlth Assurance & Purchasing Hlth Serv PHA, Riyadh, Saudi Arabia
关键词
MANAGED ENTRY AGREEMENTS; REIMBURSEMENT; REQUIREMENTS; POLICY; AGENCIES;
D O I
10.1016/j.jsps.2020.04.006
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Saudi Arabia is undergoing a massive healthcare transformation to fulfill its new, national “Vision 2030.” To align with this objective, Saudi Arabia is establishing a new, independent and evidence-based health technology assessment (HTA) entity to help it maximize health gains through efficient use of resources. This study was designed to ascertain how pharmaceutical companies perceive the creation of such a national HTA entity in Saudi Arabia; what they think about it and expect from it. To achieve the study's aim, we held a workshop in Riyadh, Saudi Arabia, lasting four and a half hours and hosted by the Saudi Ministry of Health (MOH). We invited 16 market access directors and managers from different multinational pharmaceutical companies to discuss the establishment of a national HTA entity. The findings from the workshop were structured around three axes: vision and remit; HTA method; and implementation and practical considerations. Overall, the pharmaceutical company participants were positive about HTA's value for the Saudi healthcare system and expressed willingness to adapt to meet its future requirements. © 2020 The Author(s)
引用
收藏
页码:662 / 668
页数:7
相关论文
共 42 条
[1]  
Ahmed Sabreena., 2018, The Turkish Online Journal of Design, Art and Communication (TOJDAC), P1504, DOI DOI 10.7456/1080SSE/201
[2]   Variation in Health Technology Assessment and Reimbursement Processes in Europe [J].
Akehurst, Ronald L. ;
Abadie, Eric ;
Renaudin, Noel ;
Sarkozy, Francois .
VALUE IN HEALTH, 2017, 20 (01) :67-76
[3]   What local experts expect from a health technology assessment (HTA) entity in Saudi Arabia: workshop conclusions [J].
Al-Omar, Hussain Abdulrahman ;
Attuwaijri, Abdulaziz Abdulhadi ;
Aljuffali, Ibrahim Abdulrahman .
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2020, 20 (01) :99-104
[4]  
[Anonymous], EFPIA PAT WAIT IND 2
[5]  
[Anonymous], US HLTH TECHN ASS HT
[6]   HEALTH TECHNOLOGY ASSESSMENT OF MEDICINES IN GREECE: PHARMACEUTICAL INDUSTRY EXECUTIVES' VIEWS [J].
Armataki, Eleni ;
Karampli, Eleftheria ;
Kyriopoulos, John ;
Pavi, Elpida .
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2014, 30 (02) :226-232
[7]   Patient access to medicines in two countries with similar health systems and differing medicines policies: Implications from a comprehensive literature review [J].
Babar, Zaheer-Ud-Din ;
Gammie, Todd ;
Seyfoddin, Ali ;
Hasan, Syed Shahzad ;
Curley, Louise E. .
RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY, 2019, 15 (03) :231-243
[8]   EARLY DIALOGUE IN EUROPE: PERSPECTIVES ON VALUE, CHALLENGES, AND CONTINUING EVOLUTION [J].
Balaisyte, Lina ;
Joos, Angelika ;
Hiligsmann, Mickael .
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2018, 34 (05) :514-518
[9]  
Braun V., 2006, Qualitative Research in Psychology, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA, DOI 10.1080/10875549.2021.1929659]
[10]   Stakeholder analysis: a review [J].
Brugha, R ;
Varvasovszky, Z .
HEALTH POLICY AND PLANNING, 2000, 15 (03) :239-246